Last reviewed · How we verify
2 - Insulin glargine QAM — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
2 - Insulin glargine QAM (2 - Insulin glargine QAM) — Charles Drew University of Medicine and Science.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| 2 - Insulin glargine QAM TARGET | 2 - Insulin glargine QAM | Charles Drew University of Medicine and Science | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- 2 - Insulin glargine QAM CI watch — RSS
- 2 - Insulin glargine QAM CI watch — Atom
- 2 - Insulin glargine QAM CI watch — JSON
- 2 - Insulin glargine QAM alone — RSS
Cite this brief
Drug Landscape (2026). 2 - Insulin glargine QAM — Competitive Intelligence Brief. https://druglandscape.com/ci/2-insulin-glargine-qam. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab